Haryana M Dhillon1, Ian F Tannock2, Gregory R Pond3, Corrinne Renton1, Sean B Rourke4, Janette L Vardy5,6,7,8. 1. Centre for Medical Psychology and Evidence-based Decision-making, University of Sydney, Level 6, The Lifehouse (C39Z), Sydney, NSW, 2006, Australia. 2. Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada. 3. Juravinski Hospital and Cancer Centre, McMaster University, 711 Concession Street, Hamilton, ON, L8V 1C3, Canada. 4. St. Michael's Hospital, University of Toronto, 30 Bond Street, Toronto, ON, M5B 1W8, Canada. 5. Centre for Medical Psychology and Evidence-based Decision-making, University of Sydney, Level 6, The Lifehouse (C39Z), Sydney, NSW, 2006, Australia. janette.vardy@sydney.edu.au. 6. Princess Margaret Cancer Centre, University of Toronto, 610 University Ave, Toronto, ON, M5G 2M9, Canada. janette.vardy@sydney.edu.au. 7. Concord Cancer Centre, Concord Repatriation General Hospital, Hospital Rd, Concord, NSW, 2139, Australia. janette.vardy@sydney.edu.au. 8. Sydney Medical School, University of Sydney, Concord, NSW, 2006, Australia. janette.vardy@sydney.edu.au.
Abstract
PURPOSE: Cognitive symptoms are common after cancer, but poorly associated with neuropsychological results. We previously reported colorectal cancer (CRC) patients had more cognitive impairment than controls. Here, we explore relationships between cognitive symptoms and neuropsychological domains. METHODS: Subjects with CRC (N = 362) and 72 healthy controls completed neuropsychological assessments and Functional Assessment of Cancer Therapy-Cognition (FACT-COG) at baseline (pre-chemotherapy) and 6, 12, and 24 months. Associations between neuropsychological and FACT-COG scores were explored: perceived cognitive impairment (PCI), perceived cognitive ability (PCA), impact of PCI on quality of life (CogQOL). RESULTS: Of 362 CRC subjects, 289 had loco-regional disease and 173 received chemotherapy (CTh+). At baseline, groups did not differ on total FACT-COG, PCI, or PCA scores. All scores, except PCA, were worse at 6 months in CTh+. CRC patients not receiving chemotherapy did not differ from controls on FACT-COG domains. PCA associated weakly (r = 0.28-0.34) with attention/executive function, visual memory, and global deficit score. There was no association between PCI and neuropsychological domains. Fatigue, anxiety/depression, and poorer quality of life were associated with PCI and CogQOL (r = 0.44-0.51) in CRC patients. CONCLUSIONS: No association was seen between total FACT-COG or PCI, and neuropsychological domains. A weak-moderate association was found between PCA and attention/executive function and visual memory. TRIAL REGISTRATION: The study was registered with clinicaltrials.gov (trial registration: NCT00188331). IMPLICATIONS FOR CANCER SURVIVORS: Cognitive symptoms are associated with fatigue, anxiety/depression, and poorer quality of life, and do not appear to be related to actual cognitive performance. Rates were lower than that reported in breast cancer survivors. Cognitive symptoms were greatest in those who received chemotherapy, with no significant difference between the non-chemotherapy survivors and healthy controls.
PURPOSE: Cognitive symptoms are common after cancer, but poorly associated with neuropsychological results. We previously reported colorectal cancer (CRC) patients had more cognitive impairment than controls. Here, we explore relationships between cognitive symptoms and neuropsychological domains. METHODS: Subjects with CRC (N = 362) and 72 healthy controls completed neuropsychological assessments and Functional Assessment of Cancer Therapy-Cognition (FACT-COG) at baseline (pre-chemotherapy) and 6, 12, and 24 months. Associations between neuropsychological and FACT-COG scores were explored: perceived cognitive impairment (PCI), perceived cognitive ability (PCA), impact of PCI on quality of life (CogQOL). RESULTS: Of 362 CRC subjects, 289 had loco-regional disease and 173 received chemotherapy (CTh+). At baseline, groups did not differ on total FACT-COG, PCI, or PCA scores. All scores, except PCA, were worse at 6 months in CTh+. CRCpatients not receiving chemotherapy did not differ from controls on FACT-COG domains. PCA associated weakly (r = 0.28-0.34) with attention/executive function, visual memory, and global deficit score. There was no association between PCI and neuropsychological domains. Fatigue, anxiety/depression, and poorer quality of life were associated with PCI and CogQOL (r = 0.44-0.51) in CRCpatients. CONCLUSIONS: No association was seen between total FACT-COG or PCI, and neuropsychological domains. A weak-moderate association was found between PCA and attention/executive function and visual memory. TRIAL REGISTRATION: The study was registered with clinicaltrials.gov (trial registration: NCT00188331). IMPLICATIONS FOR CANCER SURVIVORS: Cognitive symptoms are associated with fatigue, anxiety/depression, and poorer quality of life, and do not appear to be related to actual cognitive performance. Rates were lower than that reported in breast cancer survivors. Cognitive symptoms were greatest in those who received chemotherapy, with no significant difference between the non-chemotherapy survivors and healthy controls.
Entities:
Keywords:
Cognitive function; Colorectal cancer; Quality of life; Survivorship
Authors: Michelle C Janelsins; Sadhna Kohli; Supriya G Mohile; Kenneth Usuki; Tim A Ahles; Gary R Morrow Journal: Semin Oncol Date: 2011-06 Impact factor: 4.929
Authors: Patricia A Ganz; Lorna Kwan; Steven A Castellon; Amy Oppenheim; Julienne E Bower; Daniel H S Silverman; Steve W Cole; Michael R Irwin; Sonia Ancoli-Israel; Thomas R Belin Journal: J Natl Cancer Inst Date: 2013-04-19 Impact factor: 13.506
Authors: Amanda D Hutchinson; Jessica R Hosking; Ganessan Kichenadasse; Julie K Mattiske; Carlene Wilson Journal: Cancer Treat Rev Date: 2012-06-02 Impact factor: 12.111
Authors: N K Aaronson; S Ahmedzai; B Bergman; M Bullinger; A Cull; N J Duez; A Filiberti; H Flechtner; S B Fleishman; J C de Haes Journal: J Natl Cancer Inst Date: 1993-03-03 Impact factor: 13.506
Authors: Jeanne S Mandelblatt; Jonathan D Clapp; Gheorghe Luta; Leigh Anne Faul; Michelle D Tallarico; Trina D McClendon; Jessica A Whitley; Ling Cai; Tim A Ahles; Robert A Stern; Paul B Jacobsen; Brent J Small; Brandelyn N Pitcher; Estrella Dura-Fernandis; Hyman B Muss; Arti Hurria; Harvey J Cohen; Claudine Isaacs Journal: Cancer Date: 2016-07-22 Impact factor: 6.860
Authors: M Lange; F Joly; J Vardy; T Ahles; M Dubois; L Tron; G Winocur; M B De Ruiter; H Castel Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Chelsea Nicol; Tamara Ownsworth; Lee Cubis; William Nguyen; Matthew Foote; Mark B Pinkham Journal: J Cancer Surviv Date: 2019-07-17 Impact factor: 4.442
Authors: Mareye Voortman; Jolanda De Vries; Celine M R Hendriks; Marjon D P Elfferich; Petal A H M Wijnen; Marjolein Drent Journal: Sarcoidosis Vasc Diffuse Lung Dis Date: 2019-05-01 Impact factor: 0.670
Authors: Jennifer N Vega; Kimberly M Albert; Ingrid A Mayer; Warren D Taylor; Paul A Newhouse Journal: J Cancer Surviv Date: 2021-05-11 Impact factor: 4.062